WuXi Biologics (Cayman) Inc.
2269
Rang in aandelen
#991
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Aandeelprijs
$5.74
Marktkapitalisatie
$23.64B
Verandering (1 dag)
-8.79%
Verandering (1 jaar)
24.58%
Land
CN
Handel WuXi Biologics (Cayman) Inc. (2269)
Categorie
Healthcare
Winst voor WuXi Biologics (Cayman) Inc. (2269)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van WuXi Biologics (Cayman) Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van WuXi Biologics (Cayman) Inc. van 2014 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $1.04B | 56.60% |
| 2024 | $662.33M | 12.33% |
| 2023 | $589.64M | -24.09% |
| 2022 | $776.72M | 23.63% |
| 2021 | $628.25M | 108.78% |
| 2020 | $300.91M | 85.98% |
| 2019 | $161.80M | 50.86% |
| 2018 | $107.25M | 129.77% |
| 2017 | $46.68M | 84.29% |
| 2016 | $25.33M | 151.48% |
| 2015 | $10.07M | 27.28% |
| 2014 | $7.91M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
